Top Markets
#1 MowCat MowCat +48.93%
#2 Velvet Velvet +25.75%
#3 Bermuda Shorts Bermuda Shorts +24.20%
#4 Quack AI Quack AI +22.15%
#5 Audiera Audiera +19.74%
#6 Derive Derive +19.65%
#7 MarsCoin MarsCoin +14.23%
#8 Biconomy Biconomy +13.76%
#9 aPriori aPriori +13.71%
#10 Geodnet Geodnet +13.43%
Coin of the day
MowCat MowCat
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Graybug Vision, Inc. Graybug Vision, Inc.

Graybug Vision, Inc.

GRAY
Rang in aandelen #35305
Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical... Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.
Aandeelprijs
$2.70
Laatst gesynchroniseerd: 2023-05-17
Marktkapitalisatie
$4.13M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Graybug Vision, Inc. (GRAY)

Categorie

Healthcare
Winst voor Graybug Vision, Inc. (GRAY)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Graybug Vision, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Graybug Vision, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE